Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life’s ‘FL-091’ radiopharmaceutical compound into an innovative anti-cancer…
LANCASTER, Pa., July 16, 2024 /PRNewswire/ — Fulton Financial Corporation (NASDAQ: FULT) (“Fulton” or the “Corporation”) reported net income available to…